THE KOREA ECONOMIC DAILY, GLOBAL EDITION

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and development unit, have secured a bid to supply its biosimilar Hadlima (adalimumab-bwwd), a treatment for autoimmune diseases, to the US Department of Veterans Affairs (VA).

Hadlima is a biosimilar of Humira, developed by the multinational pharmaceutical company AbbVie Inc. It addresses conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

Under the contract, Samsung Bioepis and Organon will supply Hadlima to VA hospitals for the next five years.

It becomes the exclusive supplier among medications containing this active ingredient, including the original drug. The specific contract amount remains undisclosed.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com